Progyny, Inc. (PGNY) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows a positive sentiment with strong financial health, no debt, and expanding profit margins. The Q&A section reveals management's confidence despite minor headwinds, with no significant risks identified. Guidance is stable, and there is potential for upselling new products. The market cap suggests moderate volatility, aligning with a positive stock price reaction.
Key Financial Performance
Revenue Growth 9% on an as-reported basis in the quarter or 23% when excluding the impact of a large former client in the year-ago period. The transition of care agreement with this client ended as of June 30, 2025, so the results for the third quarter do not include any contribution from them.
Gross Margin 23%, reflecting healthy profitability levels.
Adjusted EBITDA Margin 17.5%, achieved while continuing to invest in product platform expansion and integration of recent acquisitions.
Operating Cash Flow More than $50 million in the third quarter, contributing to a record $156 million over the first 9 months of 2025, an increase of $29 million over the comparable period in 2024. This reflects disciplined and prudent management of the business.
CapEx $4.7 million in the third quarter, a $2.9 million increase over the prior year period, reflecting investments in enhancing member experience and integrating recent acquisitions.
Working Capital Approximately $412 million as of September 30, including $345 million in cash, cash equivalents, and marketable securities. No borrowings against the $200 million revolving credit facility and no debt of any kind.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Supplemental Plan for Fertility and Family Building: Progyny announced the first-of-its-kind supplemental plan for fertility and family building, targeting small and midsized companies. This product will be included in next year's selling season.
Progyny Global Offering: Launched a global platform providing integrated services for family building, pregnancy, postpartum, and menopause for multinational employers.
Market Expansion: Added over 80 new logos and approximately 900,000 lives this selling season, with a broad cross-section of industries and client sizes.
Diversification: Continued diversification of member base across dozens of sectors, with no single area dominating.
Revenue Growth: Revenue exceeded the high end of guidance by more than $8 million, with a 9% growth on an as-reported basis or 23% excluding a large former client.
Profitability: Achieved a 23% gross margin and a 17.5% adjusted EBITDA margin, generating over $50 million in operating cash flow this quarter.
Client Retention: Near 100% renewal rate of existing clients and covered lives for 2026.
Share Repurchase Program: Announced a new share repurchase program of up to $200 million to return value to investors.
White House Fertility Care Focus: The White House's focus on expanding access to fertility care aligns with Progyny's mission and validates its efforts over the past decade.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Uncertainty: The pipeline initially built slower than expected due to macroeconomic uncertainty earlier in the year, which could impact client decision-making and sales cycles.
Medical Cost Inflation: Historically high macro medical cost inflation poses a challenge to maintaining profitability and cost predictability for clients.
Delayed Client Decisions: Some large employers were unable to accelerate their decision-making processes, delaying potential revenue opportunities to future periods.
Client Transition Impact: The transition of care agreement with a large client ended, resulting in no revenue contribution from this client in the second half of the year.
Utilization Variability: Unexpected variability in member engagement and treatment activity could impact revenue and operational planning.
Integration of Acquisitions: Ongoing integration of recent acquisitions requires investment and operational focus, which could strain resources.
Small and Midsized Market Challenges: Developing a product for small and midsized companies to address their needs presents challenges in terms of cost predictability and market penetration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q4 2025: Projected revenue between $292.7 million to $307.7 million, reflecting growth of -1.9% to 3.1%. Excluding a large former client, growth is projected at 11.5% to 17.2%.
Revenue Guidance for Full Year 2025: Projected revenue between $1.263 billion to $1.278 billion, reflecting growth of 8.2% to 9.5%. Excluding a large former client, growth is projected at 17.8% to 19.2%.
Adjusted EBITDA Guidance for Full Year 2025: Expected adjusted EBITDA between $216 million to $220 million.
Net Income Guidance for Full Year 2025: Expected net income between $58.5 million to $61.5 million, equating to $0.65 to $0.68 earnings per diluted share.
Adjusted EPS Guidance for Full Year 2025: Expected adjusted EPS between $1.79 and $1.82.
Utilization Rate Assumptions for Full Year 2025: Narrowed assumption for full year utilization to 1.05% at the low end and 1.06% at the high end.
ART Cycles per Unique Utilizer for Full Year 2025: Maintained assumptions for full year ART cycles per unique utilizer at 0.91 at the low end and 0.92 at the high end.
Capital Expenditures for 2025: Incremental CapEx for enhancing member experience and integrating acquisitions expected to be approximately $15 million over 2024 levels.
New Product Launch for Small and Midsized Companies: Announced the first-of-its-kind supplemental plan for fertility and family building, to be included in next year's selling season.
Progyny Global Offering: Launched a global platform providing integrated services for family building, pregnancy, postpartum, and menopause for multinational employers.
Member Access to New Services in 2026: More than 2.7 million members will have access to new services in 2026, an incremental 1.2 million members compared to 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company announced a new share repurchase program for up to $200 million. This program is aimed at returning value to shareholders and is immediately available for use. The repurchase will be conducted through open market and facilitated purchases. Despite this sizable program, the company maintains its ability to invest in future growth, including product expansions, new distribution channels, and select acquisitions.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the 900,000 new covered lives in light of previous messaging about lives running lower year-over-year?
A:The management is pleased with the execution despite headwinds like a late-developing pipeline and high macro healthcare inflation. The 100,000 shortfall is attributed to a small number of client decisions and is relatively minor against the broader 7 million base. Some deals may close post-November, contributing to next year's pipeline.
Q:What is the impact of the current administration's focus on improving affordability of cash pay fertility medications on Progyny Rx business?
A:The announcement pertains to existing patient assistance programs for those without coverage and deepens discounts slightly. It is not expected to impact covered benefits or pricing for covered benefits as these programs have been around for a long time.
Q:What are the discussions with employer clients regarding layoffs and their impact on utilization?
A:Management is not seeing significant layoffs impacting utilization. Layoffs announced are small and not widespread. Employers continue to focus on member experience, quality, outcomes, and cost control, aligning with the company's value proposition.
Q:How should we think about gross profit margin modeling going forward?
A:Gross profit margins have been expanding year-over-year. Q4 is typically modeled down due to investments and staff building for the next year. Profitability is kept consistent while leveraging teams as the company grows.
Q:How do cash prices for drugs compare to net prices offered to clients?
A:Cash pricing is generally cheaper, but it varies by drug. Management emphasizes that cash prices have been around for a long time and have not influenced pricing for coverage or client conversations.
Q:What is the upsell potential for new products and how does it evolve?
A:The company meets with clients quarterly to discuss existing services and opportunities to expand. New products and services provide more opportunities to impact costs and align with client strategies, enabling ongoing upsell discussions throughout the year.
Q:How does the company manage the pool of new lives added during the selling season?
A:The company uses plan design, products purchased, industry, and client size to predict revenue contribution. Variability exists within individual clients, but the overall pool becomes predictable when rolled up.
Q:How is the company thinking about guidance given recent choppiness in utilization trends?
A:Management views the variability as minor and has factored it into guidance ranges. They do not expect significant changes in guidance methodology.
Q:What are the expectations for ART cycles per female utilizer and their impact on revenue?
A:Seasonality affects Q4 utilization due to holidays. Management does not see weakness in utilization but expects normal seasonality. ART cycles per utilizer are expected to return to historical ranges over time.
Q:Why is Rx revenue growth trending below medical revenue growth?
A:Factors include timing differences, treatment and program mixes, cost control measures, and revenue from newer products being accounted for in the fertility services line. These factors cause variations but both revenue lines are expected to grow in tandem over the long term.
Q:What is the supplemental product for small and mid-market companies?
A:It is a covered solution addressing small and mid-market companies, providing a predictable cost structure and a robust benefit offering similar to those of larger employers.
Q:What are the expectations for client and lives growth in 2026?
A:The number of clients added may appear lower due to earlier go-lives and off-cycle clients. The majority of lives contribution is expected to start next year.
Q:Will the rollout of supplemental plans impact expenses in 2026?
A:Additional resources will be required for go-to-market efforts, but the impact on profitability is not expected to be significant.
Q:What is the update on the global or international business?
A:The company has added enhanced benefits and global services this year. The full U.S. portfolio of services will be available internationally next year, continuing the momentum.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on how cash prices for drugs compare to net prices offered to clients, stating that the details vary by drug and are not helpful to discuss. Additionally, they did not provide clear expectations for ART cycles per female utilizer returning to historical ranges, citing seasonality and normal trends without specific data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Conference Instructions
Global offering
Hartley group
Hartley population
House focus
Instructions host
Member engagement
Progyny competitor
Progyny market
Progyny platform
Progyny profitability
Relations afternoon
Rx coverage
White House
access Progyny
access fertility
access service
acquisition logo
addition expansion
administration support
affirmation work
afternoon Progyny
aligns employer
announcement
benefit employee
client benefit
employer member
expansion benefit
logo life
market value
midpoint
navigation client
pregnancy postpartum
record
strength
value proposition
PGNY Transcript
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call indicates strong financial performance with a positive revenue growth outlook, efficient cash management, and a completed share repurchase program. Despite some management vagueness on RFP activity and upsell details, the Q&A reveals positive sentiment towards early commitments and new client utilization. The market cap suggests a moderate reaction, so the stock price is likely to see a positive movement between 2% to 8% over the next two weeks.
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call shows strong financial performance with a 20% revenue growth excluding a large client, a double-digit increase in EBITDA, and a significant rise in operating cash flow. Share repurchases further indicate confidence. Despite some margin compression and conservative guidance, the company is expanding its product offerings and has a positive outlook on membership and revenue growth. The Q&A section reveals some uncertainties, but overall sentiment remains positive. Given the company's market cap, a 2% to 8% stock price increase is likely over the next two weeks.
PGNY Slides
PGNY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
